Interactions between metals and α-synuclein - Function or artefact?

FEBS Journal

Volumn 274, Issue 15, 2007, Pages 3766-3774

  Brown, David R ^a  

^a University of Bath   (United Kingdom)

Author keywords

Amyloid; Copper; Lewy body; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; COPPER; METAL; PHOSPHOLIPASE D2;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; ENDOCYTOSIS; GENE MUTATION; METAL BINDING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SEQUENCE HOMOLOGY; SHORT SURVEY;

ALPHA-SYNUCLEIN; ANIMALS; ARTIFACTS; HUMANS; METALS; MUTATION; PROTEIN BINDING;

EID: 34447629079     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2007.05917.x     Document Type: Short Survey

References (77)

1. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216, 136 144.
2. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A Saitoh T (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467 475.
3. Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2, 492 501.
4. Conway KA, Harper JD Lansbury PT (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4, 1318 1320.
5. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55, 164 173.
6. Fernagut P-O Chesselet M-F (2004) Alpha-synuclein and transgenic mouse models. Neurobiol Dis 17, 123 130.
7. Goldberg MS Lansbury PT Jr. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2, E115 E119.
8. Brazilai A Melamed E (2003) Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends Mol Med 9, 126 132.
9. Xu J, Kao SY, Lee FJ, Song W, Jin LW Yankner BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8, 600 606.
10. Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR Ghetti B (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839 841.
11. Arima K, Ueda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H Kawai M (1998) Immunoelectronmicroscopic demonstration of NACP/alpha-synuclein epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 808, 93 102.
12. Bennett MC (2005) The role of alpha-synuclein in neurodegenerative diseases. Pharmacol Ther 105, 311 331.
13. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045 2047.
14. Krüger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18, 106 108.
15. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH Giasson BI (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem 280, 7800 7807.
16. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R et al. (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302, 841.
17. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167 1169.
18. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265 1269.
19. Feany MB Bender WWA (2000) A Drosophila model of Parkinson's disease. Nature 404, 394 397.
20. Huang Y, Cheung L, Rowe D Halliday G (2004) Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev 46, 44 70.
21. Vila M Przedborski S (2004) Genetic clues to the pathogenesis of Parkinson's disease. Nat Med 10 (Suppl. S58 S62.
22. Maroteaux L, Campanelli JT Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8, 2804 2815.
23. Jakes R, Spillantini MG Goedert M (1994) Identification of two distinct synucleins from human brain. FEBS Lett 345, 27 32.
24. Langston JW, Sastry S, Chan P, Forno LS, Bolin LM Di Monte DA (1998) Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. Exp Neurol 154, 684 690.
25. George JM, Jin H, Woods WS Clayton DF (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361 372.
26. Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu GM, Louis JC et al. (2000) Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. J Biol Chem 275, 34574 34579.
27. Hashimoto M, Rockenstein E, Mante M, Mallory M Masliah E (2001) Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213 223.
28. Goedert M (1997) Familial Parkinson's disease. The awakening of alpha-synuclein. Nature 388, 232 233.
29. Weinreb PH, Zhen W, Poon AW, Conway KA Lansbury PT Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709 13715.
30. Uversky VN, Li J Fink AL (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276, 10737 10744.
31. Eliezer D, Kutluay E, Bussell R Jr. Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307, 1061 1073.
32. Uversky VN, Gillespie JR Fink AL (2000) Why are 'natively unfolded' proteins unstructured under physiologic conditions? Proteins 41, 415 427.
33. Clayton DF George JM (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 58, 120 129.
34. Tobe T, Nakajo S, Tanaka A, Mitoya A, Omata K, Nakaya K, Tomita M Nakamura Y (1992) Cloning and characterization of the cDNA encoding a novel brain-specific 14-kDa protein. J Neurochem 59, 1624 1629.
35. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y Saitoh T (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 90, 11282 11286.
36. Kramer ML Schulz-Schaeffer WJ (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27, 1405 1410.
37. Davidson WS, Jonas A, Clayton DF George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273, 9443 9449.
38. Pronin AN, Morris AJ, Surguchov A Benovic JL (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 275, 26515 22622.
39. Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF et al. (1999) Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 22, 110 114.
40. Wakabayashi K, Engelender S, Yoshimoto M, Tsuji S, Ross CA Takahashi H (2000) Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 47, 521 523.
41. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239 252.
42. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA et al. (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 99, 14524 14529.
43. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE et al. (2004) Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci USA 101, 14966 14971.
44. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Spooren W, Fuss B, Mallon B, Macklin WB, Fujiwara H et al. (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Report 3, 583 588.
45. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van Der Putten H, Probst A et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 20, 6365 6373.
46. Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois J, Yu X, Dickson D, Langston WJ, McGowan E et al. (2001) Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 8, 535 539.
47. Giasson BI, Ischiropoulos H, Lee VM Trojanowski JQ (2002) The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 32, 1264 1275.
48. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA Price DL (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53->Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99, 8968 8973.
49. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA Federoff HJ (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 175, 35 48.
50. Rockenstein E, Mallory M, Mante M, Sisk A Masliaha E (2001) Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res 66, 573 582.
51. Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, Schrump S, Sondel J, Kotilinek L, Day J, Schwarzschild MA et al. (2003) Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 24, 245 258.
52. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-Clement J, Korf HW, Deller T, Braak H, Auburger G et al. (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 24, 419 429.
53. Rochet JC, Conway KA Lansbury PT Jr. (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 39, 10619 10626.
54. Yamada M, Iwatsubo T, Mizuno Y Mochizuki H (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 91, 451 461.
55. Paik SR, Shin HJ, Lee JH, Chang CS Kim J (1999) Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem J 340, 821 828.
56. Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, Zweckstetter M, Griesinger C, Jovin TM Fernandez CO (2005) Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. Proc Natl Acad Sci USA 102, 4294 4299.
57. Lee EN, Lee SY, Lee D, Kim J Paik SR (2003) Lipid interaction of alpha-synuclein during the metal-catalyzed oxidation in the presence of Cu2+ and H2O2. J Neurochem 84, 1128 1142.
58. Fernandez CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C Jovin TM (2004) NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J 23, 2039 2046.
59. Binolfi A, Rasia RM, Bertoncini CW, Ceolin M, Zweckstetter M, Griesinger C, Jovin TM Fernandez CO (2006) Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc 128, 9893 9901.
60. Sung YH, Rospigliosi C Eliezer D (2006) NMR mapping of copper binding sites in alpha-synuclein. Biochim Biophys Acta 1764, 5 12.
61. Kowalik-Jankowska T, Rajewska A, Wisniewska K, Grzonka Z Jezierska J (2005) Coordination abilities of N-terminal fragments of alpha-synuclein towards copper(II) ions: a combined potentiometric and spectroscopic study. J Inorg Biochem 99, 2282 2291.
62. Kowalik-Jankowska T, Rajewska A, Jankowska E, Wisniewska K Grzonka Z (2006) Products of Cu(II)-catalyzed oxidation of the N-terminal fragments of alpha-synuclein in the presence of hydrogen peroxide. J Inorg Biochem 100, 1623 1631.
63. Kowalik-Jankowska T, Rajewska A, Jankowska E Grzonka Z (2006) Copper(II) binding by fragments of alpha-synuclein containing M(1)-D(2)- and -H(50)-residues; a combined potentiometric and spectroscopic study. Dalton Trans 42, 5068 5076.
64. Klucken J, Outeiro TF, Nguyen P, McLean PJ Hyman BT (2006) Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J 20, 2050 2057.
65. Uversky VN, Li J Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276, 44284 44296.
66. Crowther RA, Jakes R, Spillantini MG Goedert M (1998) Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett 436, 309 312.
67. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, Pessi A, Neill D Wallace A (1998) Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 440, 71 75.
68. Giasson BI, Uryu K, Trojanowski JQ Lee VM (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274, 7619 7622.
69. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M Biere AL (1999) Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274, 19509 19512.
70. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE Lansbury PT Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97, 571 576.
71. Han H, Weinreb PH Lansbury PT Jr. (1995) The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol 2, 163 169.
72. Bodles AM, Guthrie DJ, Harriott P, Campbell P Irvine GB (2000) Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur J Biochem 267, 2186 2194.
73. El-Agnaf OM, Paleologou KE, Greer B, Abogrein AM, King JE, Salem SA, Fullwood NJ, Benson FE, Hewitt R, Ford KJ et al. (2004) A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 18, 1315 1317.
74. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K Iwatsubo T (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biol 4, 160 164.
75. Volles MJ Lansbury PT Jr. (2003) Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42, 7871 7878.
76. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985 989.
77. Yamin G, Glaser CB, Uversky VN Fink AL (2003) Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem 278, 27630 27635.